

Freedom of Information Request: Our Reference CTHB_442_18

You asked:

1. How many patients with plaque psoriasis in your LHB are currently being treated with unlicensed Fumaderm?
2. How many patients with plaque psoriasis in your LHB are currently being treated with Skilarence?
3. Is the LHB starting patients with plaque psoriasis on Skilarence?
 - a. If yes to Q3, how many new patients in the last 6 months who have not previously been prescribed unlicensed Fumaderm or fumaric acid esters?
4. Is the LHB starting patients with psoriasis on unlicensed Fumaderm?
 - a. If yes to Q4, how many patients in the last 6 months?
5. Does the LHB intend to review all patients with plaque psoriasis taking unlicensed Fumaderm in order to move them to a licensed formulation where appropriate?
6. Please describe the process in place to achieve Q5 and the anticipated completion date.
7. If the LHB does not intend to initiate Skilarence or review all patients with plaque psoriasis taking unlicensed Fumaderm, please provide an explanation why the Trust intends to continue with its current practice.

Our response:

Cwm Taf University Health Board does not use either Fumaderm or Skilarence for treatment of plaque psoriasis or any other dermatology condition. This is not a treatment that is used by Dermatologists within the Health Board, nor are there any plans to begin using this in the foreseeable future.

Under the terms of the Health Board's Freedom of Information policy, individuals seeking access to recorded information held by the Health Board are entitled to request an internal review of the handling of their requests.